Research Paper Volume 12, Issue 6 pp 5183—5194

LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer

Figure 3. AGAP2-AS1 promoted cell cycle progression and conferred gemcitabine resistance. (A) Cell cycle in RKO cells transfected with pWPXL-AGAP2-AS1 or pWPXL, and DLD-1 cells transfected with si-AGAP2-AS1 or si-NC were analyzed. (B) The sensitivity of CRC cells to gemcitabine were decreased by AGAP2-AS1. (C) Apoptosis of CRC cells after AGAP2-AS1 overexpression or knockdown in the presence of gemcitabine. *P < 0.05; **P < 0.01.